Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2026-05-15 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an official announcement of the 2025 annual general meeting (股东会) resolutions, detailing vote counts, percentages, meeting attendance, and procedural compliance. It reports the results of shareholder votes on various agenda items, fitting the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-15 Chinese
长春百克生物科技股份公司2025年度独立董事述职报告（凌虹）
Governance Information Classification · 85% confidence The document is the 2025 annual work report of an independent director for a Chinese listed company, detailing governance activities, board and committee attendance, communication with auditors and shareholders, and governance-related opinions. It is not an announcement of a report, nor a financial statement (10-K, IR, ER), nor a change of management merely announcing appointments. It focuses on the governance role and duties of the independent director, fitting the Governance Information category.
2026-04-21 Chinese
长春百克生物科技股份公司董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the principles, management structure, standards, payment, and accountability mechanisms related to the compensation of directors and senior management personnel. There is no financial data, audit information, or report of financial results. Instead, it focuses on the remuneration policies and governance related to compensation. This matches the description of Remuneration Information filings, which detail compensation for top executives and directors.
2026-04-21 Chinese
长春百克生物科技股份公司2025年环境、社会和公司治理报告摘要
Environmental & Social Information Classification · 100% confidence The document is titled as an "环境、社会和公司治理报告摘要" which translates to "Environmental, Social and Corporate Governance Report Summary." It references ESG (Environmental, Social, and Governance) topics, sustainability governance, stakeholder communication, and materiality assessments related to ESG factors. The document is a summary of the full ESG report and includes detailed information on the company's sustainability practices and governance related to ESG. It does not contain financial statements or quarterly/yearly financial results, nor is it an announcement or certification. This matches the definition of an Environmental & Social Information report (Code: SR). The document length is 3412 characters, which is consistent with a summary report rather than a full annual or interim financial report. Therefore, the appropriate classification is SR (Environmental & Social Information).
2026-04-21 Chinese
长春百克生物科技股份公司关于2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Changchun Baike Biotechnology Co., Ltd. regarding the storage, management, and actual use of funds raised in the year 2025. It includes extensive financial data on the amount of funds raised, usage over multiple years, interest income, project investment details, changes in project timelines, and compliance with regulatory requirements. The document references regulatory rules related to fundraising and fund management, includes auditor and sponsor institution opinions, and provides detailed tables on fund usage and project progress. The content is focused on the company's fundraising activities and the management of those funds, rather than a general annual report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial data, so it is not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2026-04-21 Chinese
长春百克生物科技股份公司关于召开2025年年度股东会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2025 Annual General Meeting (AGM) of Changchun Baike Biotechnology Co., Ltd., including details such as meeting date, voting methods, agenda items, and proxy forms. It does not contain financial statements or results but rather logistical and procedural information for shareholders to participate in the AGM. The document length is 3235 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2026-04-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.